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Abstract  51 
Background 52 
Charcot neuroarthropathy is a complication of peripheral neuropathy associated with 53 
diabetes which most frequently affects the lower limb.   It can cause fractures and 54 
dislocations within the foot, which may progress to deformity and ulceration. 55 
Recommended treatment is immobilisation and offloading, with a below knee non-56 
removable cast or boot. Duration of treatment varies from six months to more than one 57 
year. Small observational studies suggest that repeated assessment with Magnetic 58 
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Resonance Imaging improves decision making about when to stop treatment, but this has 59 
not been tested in clinical trials.  This study aims to explore the feasibility of using serial 60 
Magnetic Resonance Imaging without contrast in the monitoring of Charcot 61 
neuroarthropathy to reduce duration of immobilisation of the foot. A nested qualitative 62 
study aims to explore participants’ lived experience of Charcot neuroarthropathy and of 63 
taking part in the feasibility study.  64 
 65 
Methods 66 
We will undertake a two arm, open study, and randomise 60 people with a suspected or 67 
confirmed diagnosis of Charcot neuroarthropathy from five NHS, secondary care 68 
multidisciplinary Diabetic Foot Clinics across England. Participants will be randomised 1:1 to 69 
receive Magnetic Resonance Imaging at baseline and remission up to 12 months, with 70 
repeated foot temperature measurements and x-rays (standard care plus), or standard care 71 
plus with additional three-monthly Magnetic Resonance Imaging until remission up to 12 72 
months (intervention). Time to confirmed remission of Charcot neuroarthropathy with off-73 
loading treatment (days) and its variance will be used to inform sample size in a full-scale 74 
trial.  We will look for opportunities to improve the protocols for monitoring techniques and 75 
the clinical, patient centred, and health economic measures used in a future study. For the 76 
nested qualitative study, we will invite a purposive sample of 10-14 people able to offer 77 
maximally varying experiences from the feasibility study to take part in semi-structured 78 
interviews to be analysed using thematic analysis.  79 
 80 
5 
 
Discussion 81 
The study will inform the decision whether to proceed to a full-scale trial. It will also allow 82 
deeper understanding of the lived experience of Charcot neuroarthropathy, and factors that 83 
contribute to engagement in management and contribute to the development of more 84 
effective patient centred strategies. 85 
 86 
Trial registration ISRCTN, ISRCTN, 74101606. Registered on 6 November 2017,  87 
http://www.isrctn.com/ISRCTN74101606?q=CADom&filters=&sort=&offset=1&totalResults88 
=1&page=1&pageSize=10&searchType=basic-search  89 
 90 
Keywords Charcot neuroarthropathy, diabetes, MRI, temperature monitoring, X-ray, patient 91 
experience, feasibility study. 92 
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Background 101 
Charcot neuroarthropathy (CN) is a complication of peripheral neuropathy associated with 102 
diabetes which most frequently affects the lower limb.   It can cause fractures and 103 
dislocations within the foot, which may progress to deformity and ulceration. The symptoms 104 
include redness, warmth and swelling in the foot and/or leg. This inflammation can lead to 105 
fractures in the bones and can damage joints, affecting the shape and function of the foot.  106 
It was first described 140 years ago (1), however it remains a poorly understood and 107 
frequently overlooked complication of diabetes (2). 108 
 109 
Population-based studies have estimated a life time cumulative incidence for CN of 0.4% to 110 
1.3% in people with diabetes, rising to 13% in people at high risk who attend diabetic foot 111 
speciality clinics (3). In 2018 a regional survey of 205,033 people with diabetes in the East 112 
Midlands,  UK reported a point prevalence of 0.04% (4).  CN is associated with increased 113 
length of stay and use of medical resources (5).   114 
 115 
The aim of treatment is to stop the inflammatory process, relieve pain and maintain foot 116 
architecture reducing the risk of future ulceration and amputation (6). The current 117 
international consensus is that the foot should be immobilised in a below knee non-118 
removable cast or boot, with weekly or fortnightly review by healthcare professionals 119 
working in specialist multidisciplinary diabetic foot clinics (7). The immobilisation minimises 120 
the potential for any further damage to the foot structure. Immobilisation is continued until 121 
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remission, defined as the absence of clinical signs of inflammation, measured using skin 122 
surface infra-red thermography, and X-rays showing signs of bone healing and union (8). 123 
 124 
The evidence base for the treatment of CN is weak. It is based on studies from a few centres 125 
which used retrospective designs and case note review methods using small sample sizes, 126 
typically in the range of 9-55 participants (3,9–13).  Many studies failed to standardise 127 
monitoring, treatment and outcomes, which makes direct comparison between studies 128 
difficult. 129 
 130 
Studies from the UK have shown a median time to remission of 9-12 months (9,13,14). 131 
However, US studies report considerably shorter time to remission of 3-5 months (3,10–12). 132 
Studies from Brazil and Germany show remission times of 3-12 months and 3-6 months, 133 
respectively (15,16). Shorter treatment times could be related to reported differences in the 134 
relapse rates for CN, between 12-33% (13,17–19), but without clear and consistent 135 
definitions for remission and relapse this is unknown.  There is also variation in the reported 136 
annual major amputation rates in people with CN from two different case series from 137 
hospitals in the USA: 2.7% and 6.6% (20,21) 138 
 139 
The reasons for the variation are not understood but could include people’s characteristics 140 
at the start of the treatment, different techniques for monitoring CN, different protocols for 141 
the same monitoring techniques, variations in approach to off-loading, and variability in 142 
study design. These could either underestimate or overestimate treatment duration.  143 
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 144 
Temperature difference between the feet is one of the most frequently used methods to 145 
monitor CN. It is recommended in the 2015 National Institute for Health and Care Excellence 146 
guidance on diabetic foot problems (22). The most recent systematic review (8) published in 147 
2013 recommends that immobilisation is continued until the temperature difference 148 
between the feet is less than 1-2 °C, and no further radiological changes on imaging have 149 
occurred. However this recommendation is only based on level IV evidence, i.e. case series 150 
(8). There is variability in the protocols used to measure the temperature difference 151 
between the feet. The most detailed protocol for measuring temperature discrepancy 152 
requires a 15 minute acclimatisation period, controlled ambient air temperature, and 153 
readings collected from nine different places on each foot (23). In addition,  plain X-rays 154 
demonstrate damage to the bone and joints rather than disease activity (inflammation). 155 
 156 
Studies show inconsistency in the methods for monitoring and monitoring devices used 157 
(13,17–19,23–25). These factors may overestimate or underestimate the degree of 158 
inflammation, so treatment may be discontinued too early or continued for longer than 159 
necessary.  The presence of simultaneous bilateral foot disease or the absence of a 160 
contralateral limb through prior amputation invalidates the use of temperature 161 
measurement as a tool for identifying disease remission.  162 
 163 
The National Institute for Health and Care Excellence recommends the use of MRI in 164 
determining a diagnosis of CN in the early stages of disease when no signs are evident on 165 
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plain radiology (30). However serial MRI is not widely used in routine clinical practice as a 166 
tool to monitor for signs of disease remission in CN (27).  One prospective study using MRI 167 
with contrast reported that mean healing times were associated with contrast uptake 168 
assessed at baseline (28). A further two retrospective studies looked at bone marrow 169 
oedema. One study reported decreasing bone marrow oedema in 69% of follow up images 170 
(29) and the second study found a significant positive correlation between intensity of bone 171 
marrow oedema on MRI and clinical measures (30). This emerging evidence suggests that 172 
MRI may be useful for the surveillance of active CN.  The findings from MRIs could be 173 
adopted as the criterion standard for establishing disease activity and remission.   174 
 175 
The use of MRI in monitoring CN therefore needs to be formally evaluated in a trial (29). 176 
However, the evidence to support a full randomised controlled trial is presently insufficient.  177 
We will conduct a randomised feasibility study to understand the proportion of people who 178 
meet the eligibility criteria, the number of eligible participants recruited, the number of 179 
participants who receive an alternative diagnosis, and the proportion of participants who 180 
withdraw. Time to MRI confirmed remission of CN with off-loading treatment (in days) and 181 
its variance will be used to inform sample size in a main trial.  We will look for opportunities 182 
to improve the protocols for monitoring techniques in a future trial. We will examine the 183 
feasibility of a range of clinical, patient centred, and health economic measures We are 184 
using a randomised controlled trial as it is considered the gold standard for evaluating 185 
efficacy in clinical research (31).  186 
 187 
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As part of the feasibility study we will carry out a qualitative study to further the 188 
understanding of people’s experiences of living with CN and the factors that contribute to 189 
people’s engagement in their treatment. Previous qualitative studies have demonstrated 190 
the importance of people’s perspectives in order to promote engagement in the prevention 191 
and management of diabetic foot ulcerations (32–34).  What may be people’s views and 192 
experiences of CN is an under-researched area (35). In the UK treatment times for CN  are 193 
between 9-12 months (14), which is longer than those for foot ulceration, where treatment 194 
times are no more than 12 weeks for half of the people (36). This means that evidence on 195 
people’s experiences of foot ulceration may not transfer to CN.   196 
 197 
In summary, there is a lack of evidence to support the use of monitoring techniques in CN. 198 
Healthcare professionals rely on methods and devices which do not accurately reflect 199 
disease progression, and decision making about discontinuing or prolonging immobilisation 200 
is challenging. A lack of understanding on people’s experiences of living with CN, means their 201 
needs and wishes may be neglected with current treatments, and are not being considered when 202 
developing new treatment strategies and pathways.  203 
 204 
Aim and objectives 205 
This study aims to explore the feasibility of using serial MRI without contrast in the 206 
monitoring of CN to reduce duration of immobilisation of the foot, in order to decide 207 
whether a large-scale trial is warranted. We will assess eligibility, recruitment, retention and 208 
withdrawal rates. Time to MRI confirmed remission of CN with off-loading treatment (days) 209 
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and its variance will be used to inform sample size in a main trial.   We will also examine the 210 
feasibility of collecting clinical, patient centred and health economic measures.  The nested 211 
qualitative study aims to explore the dimensions of lived experience of CN and the 212 
participants’ experiences of taking part in the feasibility study.  213 
 214 
Methods 215 
Study Design (Figure 1)  216 
This is a two-arm, open, randomised controlled trial, investigating the feasibility of using 217 
serial MRI to monitor CN. The study will last for a maximum of 3 ½ years. The study is 218 
divided into two phases. Phase one, the active phase, will last until the CN is in remission, or 219 
a maximum of 12 months. Phase two, the follow-up phase, will last for six months after 220 
remission (Figure 1). The maximum time a participant will be in the trial is 18 months. 221 
 222 
The decision to use an open label design was pragmatic: the MRIs will be reported by 223 
radiologists and interpreted by the healthcare professionals working in multidisciplinary 224 
specialist diabetic foot clinics. As the reporting of MRIs relies on comparison to previous 225 
images, this will indicate the trial arm the participant has been randomised to.  226 
 227 
The trial has been reviewed and approved by East Midlands - Derby Research Ethics 228 
Committee, 04/10/2017, ref: 17/EM/0288.  229 
 230 
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Setting 231 
The setting will be multidisciplinary specialist diabetic foot services at five NHS Hospital 232 
Trusts in England.  233 
 234 
Randomisation 235 
A randomisation scheme has been generated by the trial statistician. Allocation will be 236 
stratified by centre. Participants will be randomised using a web-based randomisation 237 
process on a 1:1 basis to: (a) Immobilisation discontinued on the basis of clinical remission 238 
determined by skin temperature measurement, which triggers an MRI (standard care plus) 239 
or (b) Standard care plus and additionally the serial use of MRI at 3, 6, 9 and 12 months to 240 
identify disease remission and thus discontinuation of immobilisation (intervention).  241 
 242 
Sample size  243 
As this is a feasibility study a power calculation is not required. An allowance has been made 244 
for up to 10-15% of participants to be withdrawn from the study due to an alternative 245 
diagnosis. The sample size will be 60 people with 30 participants per arm, based on 246 
recommended sample sizes between 24 – 50 for a feasibility study (37,38).  We will invite a 247 
purposive subsample of 10-14 participants from the feasibility study to take part in the 248 
qualitative study.  249 
 250 
Participants – Inclusion and exclusion criteria   251 
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Participants will be people with diabetes as defined by the World Health Organisation (39) 252 
and a suspected or confirmed diagnosis of CN who are attending NHS multidisciplinary 253 
specialist diabetic foot services. They will be identified, recruited and consented by the 254 
healthcare professionals working in the foot clinics, these will include podiatrists, nurses and 255 
doctors. The full inclusion and exclusion criteria are shown in Table 1. The main exclusion 256 
criteria were selected because: 1) they are contra-indications to having an MRI scan, 2) 257 
bilateral disease prevents temperature comparison with the contra-lateral limb, and 3) co-258 
morbidities may alter people’s inflammatory response. A confirmed diagnosis of CN can 259 
take several weeks, so participants will be recruited as early as possible to accurately collect 260 
length of time in below knee non-removable cast or boot. If the clinical team decides on an 261 
alternative diagnosis during the trial, then the participant will exit the study. We anticipate 262 
that alternative diagnosis will include infection, gout, arthritis, soft tissue injuries, or deep 263 
vein thrombosis. Follow-up care will be provided by the appropriate clinical team. 264 
 265 
For the qualitative study we have identified five participant characteristics which will 266 
purposively inform the sampling framework and will seek to maximise variation in gender, 267 
age, history of previous foot complications, duration of treatment for the current episode of 268 
CN, and employment status. In addition to these factors we will also ensure that 269 
participants equally represent both study arms. 270 
 271 
Outcomes 272 
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We will measure a range of feasibility, clinical and patient centred outcomes (Table 2). We 273 
will record time to MRI confirmed remission of CN with off-loading treatment (days) and its 274 
variance will be used to inform the sample size for a full-scale trial.  275 
 276 
For participants in the standard care arm remission is defined as a temperature difference 277 
of ≤ 20C which is maintained or improves on two separate consecutive occasions for a 278 
period of at least four weeks (8) or at the discretion of the clinical team when temperature 279 
difference is not valid; for example in the presence of bilateral foot disease. In the standard 280 
care plus arm this will then trigger an MRI. In the intervention arm remission is defined as an 281 
absence of sub-chondral bone marrow oedema on MRI, as reported by a radiologist and the 282 
absence of clinical signs and symptoms of CN. The clinical team will interpret the results of 283 
the MRI report to determine remission. 284 
 285 
The final visit will be six months after remission. During these six months we will continue to 286 
monitor the foot using the standardised assessment of foot temperature for any clinical 287 
signs that the CN has relapsed.  We have defined relapse as a temperature difference of 288 
>2°C compared to the contralateral foot maintained for two or more occasions or further 289 
changes on imaging. The final decision as to whether the CN has relapsed will be at the 290 
discretion of the clinical team.  291 
 292 
We will explore the feasibility of collecting resource use and quality of life data, to inform 293 
the design of the health economics component of a future definitive trial. Data on all 294 
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primary care and secondary care visits and admissions to hospital will be collected. Time off 295 
work and levels of informal care will also be assessed. We will use the qualitative interviews 296 
to gain a deeper, more detailed and rounded contextualised understanding of participants’ 297 
lived experience of CN and of taking part in this study. 298 
 299 
Planned interventions 300 
Standard care plus participants will receive standard care for the assessment and 301 
management of CN and any other foot problems; alongside this we will collect study 302 
measures (Figure 2).  If participants have not had a recent diagnostic X-ray or MRI (within 303 
the last three weeks) this will be requested. In this study we have standardised the 304 
assessment of foot temperature to monitor CN by using the same device, the Thermofocus 305 
01500A3®. Every 14 days the temperature of both feet will be recorded at intervals of 5 306 
minutes, starting at the removal of the off-loading device and up to 15 minutes. The sites 307 
where the temperature will be measured are based on the classification tool developed by 308 
Sanders and Frykberg (40). We will classify the stage using the modified (41) Eichenholtz 309 
classification tool (42)  and location of the CN (40) at baseline using anterior/posterior, 310 
oblique and lateral weight bearing X-rays.   311 
 312 
Intervention: In addition to standard care plus, participants in the intervention arm will 313 
receive serial MRIs at 3, 6, 9 and 12 months. Intervention participants will not undergo 314 
further MRIs once remission has been diagnosed, i.e., if remission is diagnosed at 6 months 315 
the MRIs at 9 and 12 months will not occur.  316 
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 317 
Study Procedures (Figure 2) 318 
The schedule of enrolment, interventions and assessments is shown in Figure 2. After giving 319 
written informed consent (see Appendix 1) participants will attend for visits every 14 days 320 
until remission. All visits will take place in multidisciplinary foot clinics. Wherever possible 321 
study measurements and trial interventions will coincide with the participant’s existing clinic 322 
appointments. This will reduce study burden which is likely to help increase recruitment and 323 
retention rates. The study protocol (v1.3, dated 22nd July 2019) is based on the Standard 324 
Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 Statement for 325 
protocols of clinical trials (see Additional file 1). 326 
 327 
Prior to participating in the interviews about the lived experience of CN, participants will 328 
receive a further patient information sheet explaining the purpose of the interview and will 329 
be asked to complete another consent form (see Appendix 2). All the qualitative interviews 330 
will be carried out by the first author (CG), using a semi-structured approach. The topic 331 
guide will include a number of probes designed to prompt the participant to increase the 332 
level of detail and depth of the information provided from the participants’ own viewpoint. 333 
Interviews will last approximately 30-40 minutes in a place of the participant’s choosing. The 334 
interviews will be audiotaped (with the participant’s permission) and transcribed in full to 335 
capture language and their own expressions.  336 
 337 
Analyses 338 
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Quantitative analysis 339 
The feasibility measures including eligibility, recruitment, retention, and withdrawals will be 340 
reported as point estimates with 95% confidence intervals. There is no intention to conduct 341 
any formal comparative analyses for these measures, though levels of missing data will be 342 
explored with respect to certain baseline characteristics, e.g., age and measures of disease 343 
severity. Variability in outcomes (e.g. standard deviation) will be estimated with 95% 344 
confidence intervals to inform the sample size calculations for a full-scale trial. Any 345 
between-group efficacy analyses will only be exploratory.  There are no plans for any 346 
interim analyses. 347 
 348 
We will assess progression of foot deformity by comparing X-rays at baseline, remission and 349 
six months post remission. We will measure the change in the Calcaneal Inclination, Talar 350 
Declination and Talo-first metatarsal angle between the X-rays. People who have undergone 351 
previous minor amputation and/or previous orthopaedic surgical fixation of the foot which 352 
alters or removes the anatomical landmarks of the foot will be excluded from this analysis 353 
due to the absence of bony landmarks.  354 
 355 
The main purpose of the economic analysis is to inform how the data on costs and effects 356 
would be collected within a definitive study. Thus, we will estimate completion rates and 357 
seek to identify big cost drivers, in order to inform this decision. A preliminary cost-358 
effectiveness analysis will also be performed, although the findings will be treated with 359 
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caution. As such, we will estimate the mean incremental cost and mean QALY gain 360 
associated with the intervention compared to standard care plus.  361 
 362 
Qualitative analysis 363 
The qualitative interviews will be analysed using Inductive Thematic Analysis using the six-364 
step model (43).  The first author (CG) will read all the transcribed interviews to record 365 
emerging ideas. The interviews will then be subjected to line by line coding using the NVivo 366 
data management package. The coding framework will be refined by a second researcher, 367 
who will cross-check it against a small sample of transcripts. A modified framework 368 
approach will be used to organise the analysis. The coded data will be subjected to a 369 
thematic analysis, identifying key categories and themes from the data, ensuring that all 370 
participants’ responses are adequately captured, and their meaning authentically 371 
interpreted.  This approach will provide rich descriptions of the data representing accounts 372 
of the diverse and personal experiences of people who have taken part in the study and 373 
been treated for acute Charcot neuroarthropathy.  374 
 375 
Data management and quality assurance  376 
We will set up a Trial Management Group to assist with co-ordination and strategic 377 
management of the feasibility study. An initial on-site initiation visit will be completed by CG 378 
prior to the sites opening. The primary method of data collection by the research teams will 379 
be direct online entry of data onto a purpose-designed secure password-protected 380 
electronic case record form. The database complies with data protection requirements (44) 381 
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on confidentiality and anonymity.  Quality management and monitoring procedures have 382 
been discussed and agreed with the sponsor. Central monitoring has been considered 383 
appropriate for this study with the option to escalate findings and conduct ‘for-cause” on-384 
site triggered monitoring visit if indicated. We will review completed consent forms and 385 
selected data points for quality assurance at each site within a week after randomisation of 386 
the first participant. Subsequent monitoring will be completed at six monthly intervals to 387 
coincide with the Trial Management Group meetings and at the end of data collection. 388 
  389 
Safety reporting 390 
Safety monitoring and reporting of adverse events has been discussed and agreed with the 391 
sponsor. The study has been assessed as low risk, therefore there will not be a Data 392 
Monitoring Committee. The intervention consists of increased frequency of MRI scans 393 
without contrast, so a pragmatic approach to safety reporting will be used.  MRI scans will 394 
be performed in NHS hospitals under routine clinical protocols.  Adverse events resulting 395 
from MRI scans will be reported by the research teams in line with the Hospital Trust’s 396 
clinical incident reporting policy. A copy of the anonymised incident form will be forwarded 397 
to the Chief Investigator (CG) and reviewed by the Trial Management Group.  All other 398 
anticipated events, e.g., ulceration, infection, amputation, pain, falls and death will be 399 
recorded as secondary outcomes.   400 
 401 
Discussion 402 
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CN is a poorly understood and under researched complication of diabetes, associated with 403 
increased morbidity and mortality compared to people with diabetes without peripheral 404 
neuropathy. Evidence is lacking about factors that influence the unexplained variation in 405 
treatment times, relapse rates and complications such as ulceration and amputation.  We 406 
have also identified a lack of evidence to support the efficacy of current monitoring 407 
techniques in CN. There is evidence from small studies that MRI may be superior to current 408 
methods of monitoring for remission in CN, but this has not been formally evaluated using 409 
robust designs. The results of this feasibility study will inform the decision about progressing 410 
to a full-sized pragmatic randomised controlled trial: the number of sites required, trial 411 
design, the frequency of MRI monitoring, and the choice of process and outcome measures. 412 
The embedded qualitative study will provide contextual and meaningful insight into 413 
people’s experiences of living with CN and what factors they see as contributing to their 414 
engagement with the prescribed treatment. Secondly, the qualitative study will advance our 415 
understanding of how the condition impacts on participants’ quality of life and may 416 
contribute to future work on Patient Reported Outcomes Measures in this area (45). Finally, 417 
the findings from the qualitative study will provide additional insights into aspects of the 418 
trial design and processes that could be improved, in terms of engagement of, and 419 
acceptability to participants, based on the participants’ experience of involvement in the 420 
feasibility study. These aspects could include feedback on the frequency of trial visits, the 421 
length of the active and follow-up phases of the trial. and the choice and frequency of 422 
completing validated questionnaires. The results of this study will be disseminated to 423 
researchers, clinicians, people with diabetes and relevant stakeholders through 424 
presentations, publications, and social media press releases.   425 
 426 
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Trial Status 427 
The CADOM trial originally opened for recruitment in December 2017 and is currently 428 
recruiting participants. Recruitment will continue until the end of November 2019.   429 
 430 
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ABPI   Ankle brachial pressure index 432 
BMI   Body mass index 433 
CN         Charcot neuroarthropathy 434 
eGFR     Estimated Glomerular Filtration rate, ml/min 435 
EQ-5D-5L Euroqol 5D 436 
F   Follow up visit 437 
HADS  Hospital Anxiety and Depression Scale 438 
HbA1c   Glycated haemoglobin (A1c), mmol/mol 439 
MRI  Magnetic Resonance Imaging 440 
NHS  National Health Service 441 
R   Remission 442 
SF-12  Medical Outcomes Short-Form Health Questionnaire  443 
VAS   Visual analogue scale 444 
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 447 
Ethical approval and consent to participate 448 
The trial has been reviewed by East Midlands - Derby Research Ethics Committee, 449 
04/10/2017, ref: 17/EM/0288. The trial is registered on the ISRCTN registry: reference 450 
number ISRCTN74101606.  All participants will provide written consent to take part in the 451 
feasibility trial and will be re-consented by a member of the research team prior to 452 
participating in the qualitative interviews. In the future if amendments to the protocol are 453 
required the Chief Investigator (CG) will work with the sponsor to apply for approval from 454 
Research Ethics Committee and the Health Research Association. Following approval of the 455 
amendments this will be cascaded to the research sites. The NHS indemnity scheme will 456 
apply to the potential liability of the sponsor for harm to participants arising from the 457 
management and conduct of the research.  458 
 459 
Consent for Publication 460 
Not applicable  461 
 462 
Availability of data and materials  463 
The datasets generated and/or analysed during the current trial will be available from the 464 
corresponding author on reasonable request, provided appropriate credit is attributed to 465 
the original authors and the data source. 466 
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Table 1 – Inclusion and exclusion criteria 492 
 493 
 494 
 495 
Inclusion Criteria Exclusion Criteria 
Participants who are willing and have capacity 
to give informed consent. 
 
People who have received a transplant and 
others receiving immunosuppressant therapy 
or using long-term oral glucocorticoids other 
than in the routine management of 
glucocorticoid deficiency. Participants on a 
low dose of oral glucocorticoids (<10mgs for 
≤7 days) are eligible to participate in the 
study. 
People with diabetes as diagnosed by the 
WHO criteria  
http://www.who.int/diabetes/publications/di
agnosis_diabetes2011/en/  
Participation in another intervention study on 
active CN. 
Age 18 years or over. Contra-indication for MRI. 
New or suspected diagnosis of acute CN (no 
previous incidence of acute CN within the last 
6 months on the same foot) treated with off-
loading. 
Treatment for previous suspected CN on the 
same foot in the last 6 months. 
Understand written and verbal instructions in 
English. 
Suspected or confirmed bilateral active CN at 
presentation. 
 Active osteomyelitis at randomisation 
 Previous contralateral major amputation. 
 Inability to have an MRI scan. 
 People receiving palliative care. 
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 496 
Table 2 – Feasibility, clinical efficacy and patient reported outcomes 497 
Feasibility outcomes Clinical efficacy outcomes 
Collected – all study visits  
Patient reported outcomes  
Collected – baseline, 3 monthly until remission, 
then at 1 and 6-months post remission 
The proportion of patients who 
meet the eligibility criteria 
Number of new ulcerations on the 
index foot  
 
Health related quality of life 
measured: 
Short Form 12 questionnaire (SF-
12) (46) 
EuroQol-5D-5L questionnaire (EQ-
5D-5L) (47) 
The number of eligible patients 
recruited 
Number of new ulcerations on the 
index or contralateral foot 
Hospital Anxiety and Depression 
Scale (HADS) (48) 
 
The number of participants in 
which an alternative diagnosis is 
made during the active phase of 
the trial 
 
Number of new infections on the 
index or contralateral foot  
Pain as assessed by Visual 
Analogue Scale (VAS) 
The proportion of patients that 
withdraw or are lost to follow up. 
The term ‘withdrawal’ 
encompasses two potential 
scenarios; withdrawal due to loss 
of consent or withdrawal due to 
death 
 
Number of minor and major 
amputations on the index foot or 
contralateral at the end of the 
follow up phase of the study 
 
Statistical parameters of the key 
outcome measures to inform a 
sample size calculation for a 
definitive trial  
 
Number and severity of falls 
(Hopkins Fall Grading System)(49) 
 
Ability to collect quality of life and 
resource use data 
The number of participants in each 
arm requiring further intervention 
for CN (e.g. further immobilisation) 
within 6 months of remission 
 
 498 
 499 
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 500 
 501 
Figure 1 – Patient flow diagram 502 
 503 
 504 
 505 
 506 
  507 
Query Charcot -Point of Diagnosis 
Check eligibility criteria 
Invite people to take part in the study and 
issue participant with information sheet 
Consent for participation 
Randomisation n=60 
Intervention n=30 
Clinical remission on the basis of  
MRI defined disease remission  
at 3, 6, 9 or 12m 
Standard care plus n=30 
Clinical remission determined by 
skin temperature 
If no remission 
after 12months 
participants will 
exit the study and 
continue under the 
care of their usual 
clinical team 
Remission 
within 12 months 
Exit Study 
1, 2 and 3 month follow 
up 
6 month follow up 
Standard care plus 
MRI ordered 
Qualitative 
Interviews 
n= 10-14 
NO YES 
YES 
 Phase one 
ACTIVE 
Phase two 
FOLLOW-UP 
27 
 
Figure 2 - Schedule of enrolment, interventions and assessments  508 
  Active phase (maximum 12 months) R Follow up phase 
Visit Number  1  6  11  18  26  F1 F2 F3 F4 
Month  0  3  6  9  12  1 2 3 6 
Enrolment                
Information sheet  *               
Consent  *              
Randomisation  *              
Participant characteristics                 
Medical history  *              
HbA1c & eGFR  *              
Foot surgical history  *              
Medications  *              
Classification of CN  *              
Foot assessment                 
Foot pulses  *              
ABPI  *              
10g monofilament  *              
Neurotheisometer  *              
Foot temperatures  * * * * * * * * * * * * * * 
Treatment                
Off-loading/footwear  * * * * * * * * * * * * * * 
Interventions                
MRI (standard care plus)           *     
Serial MRI (intervention)    *  *  *  *      
Clinical outcomes                
Ulceration  * * * * * * * * * * * * * * 
Infection  * * * * * * * * * * * * * * 
Amputation  * * * * * * * * * * * * * * 
Falls  * * * * * * * * * * * * * * 
BMI  *  *  *  *  * *    * 
X-ray               * 
Patient centred outcomes                
VAS - pain  *  *  *  *  *  *   * 
HADS  *  *  *  *  *  *   * 
EQ-5D-5L  *  *  *  *  *  *   * 
SF-12  *  *  *  *  *  *   * 
Health economic 
outcomes 
 
              
Issue patient diary  * * * * * * * * *      
Collect patient diary   * * * * * * * * *     
Qualitative Study                
Interview                
 509 
Active phase - while the CN is active participants will attend every 14 days, up to a maximum of 26 visits. 510 
Follow up phase – once CN is in remission participants will transfer into the follow-up phase of the study for six months.  511 
Classification of CN – accordingly to the Sanders and Frykberg and the modified Eichenholtz classification tools 512 
 513 
Abbreviations 514 
ABPI – Ankle brachial pressure index  515 
BMI – Body mass index 516 
CN – Charcot neuroarthropathy 517 
eGFR – Estimated Glomerular Filtration rate, ml/min 518 
R – Remission 519 
SF-12 - Medical Outcomes Short-Form Health 520 
Questionnaire  521 
VAS – Visual analogue scal522 
EQ-5D-5L - Euroqol 5  523 
F – Follow up visit  524 
HADS - Hospital Anxiety and Depression Scale 525 
HbA1c – glycated haemoglobin (A1c), mmol/mol 526 
MRI – Magnetic Resonance Imaging 527 
 528 
529 
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Appendix 1 – Informed consent form - feasibility trial 1 
                                                                                                             Insert local 2 
header  3 
A study to assess the use of serial MRI to reduce treatment times in 4 
Charcot in people with diabetes. 5 
 6 
(Short title: CADOM) 7 
 8 
Charcot neuroArthropathy Diagnostic Outcome Measures  9 
 10 
Patient Consent Form 11 
 12 
Principal Investigator:…………………………………………………….. 13 
 14 
Patient Study ID: …..………………..  Initials: ………………          15 
 16 
Please initial each box 17 
 18 
1. I confirm that I have read and understand the information sheet  19 
 Version 1.2 10th January 2019 for the above study. I have had the 20 
opportunity to ask questions and been given satisfactory answers. 21 
 22 
2. I have been given a full explanation of the purpose of the study and  23 
what I will be expected to do. 24 
 25 
3. I understand that my medical notes and data collected during the  26 
Study may be looked at by individuals from the Clinical Trials Unit at  27 
the University of East Anglia, from regulatory authorities or from the 28 
NO YES 
  33 
 
 1 
NHS Trust, where it is relevant to my taking part in this research, I give  2 
permission for these individuals to have access to my records. 3 
 4 
4.  I understand that my participation is voluntary and that I am free to  5 
withdraw at any time without my medical care or legal rights being  6 
affected 7 
 8 
5. I consent to the storage including electronic, of personal information for 9 
the purposes of this study. I understand that any information that could  10 
identify me will be kept strictly confidential and that no personal  11 
information will be included in the study report or other publication.  12 
 13 
6. I understand that even if I withdraw from the above study, the data  14 
collected from me up to that point will be used in analysing the results  15 
of the study.  16 
 17 
7. In the event that the MRI or X-ray shows a previous unknown condition 18 
that might need further medical or surgical intervention I agree to the 19 
research team referring me on as necessary and informing my GP. 20 
 21 
8. I understand that information held by the NHS and records maintained  22 
by the NHS Information Centre may be used to keep in touch with me 23 
and my health status. I give my permission to register my identifiable 24 
details with the NHS Information Centre.  25 
 26 
9. I agree to being contacted by the research team when the Charcot  27 
has settled, to ask if I would consider taking part in an interview.  28 
The interview would involve discussing the experience of being            29 
diagnosed and treated for Charcot, and being involved in this study 30 
 31 
10. I give permission for a copy of this consent form to be kept confidentially 32 
and securely by the Norwich Clinical Trials Unit. 33 
 34 
 35 
ICF CADOM study Version 1.3 23rd January 2019   36 
IRAS 222668 37 
YES NO 
 
 
  34 
 
 1 
 2 
11. I am happy to be contacted to receive updates on how the study 3 
is progressing and to be informed about the results of the study at the 4 
end 5 
 6 
12. I agree to take part in the study.    7 
 8 
 9 
……………………………………….                ……………...                ……………………………………. 10 
Name of the patient (Print)      Date         Patient’s signature  11 
 12 
……………………………………….                ……………...              ……………………………………….       13 
Name of person taking consent       Date                   Signature 14 
(Print) 15 
 16 
Original to be retained and filed in the site file. 1 copy to patient, 1 copy to be 17 
filed in patient’s notes 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
ICF CADOM study Version 1.3 23rd January 2019   28 
IRAS 222668 29 
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Appendix 2- Informed consent form – qualitative interviews 1 
                                                                                                   Insert local 2 
header 3 
                                                                      4 
Interviews 5 
 6 
Experiences of being treated for Charcot neuroarthropathy and views 7 
about taking part in the clinical trial. 8 
 9 
(Short title: CADOM) 10 
 11 
Charcot neuroArthropathy Diagnostic Outcome Measures  12 
 13 
Patient Consent Form 14 
 15 
 16 
Principal Investigator: …………………………………………………….. 17 
 18 
Patient Study ID: …..………………..  Initials: ………………          19 
 20 
   Please initial each box 21 
 22 
1. I confirm that I have read and understand the information sheet  23 
Version 1.1 dated 25th August 2017 for the above study. I have had the          24 
opportunity to ask questions and been given satisfactory answers. 25 
 26 
2.  I have been given a full explanation of the purpose of the study and  27 
what I will be expected to do. 28 
 29 
3. I understand that my medical notes and data collected during the study 30 
may be looked at by individuals from the Clinical Trials Unit at the  31 
University of East Anglia, from regulatory authorities or from the NHS  32 
Trust, where it is relevant to my taking part in this research, I give                     33 
permission for these individuals to have access to my records. 34 
 35 
Qualitative Interviews CADOM study Version 1.2, 1st May 2018  36 
IRAS 222668 37 
 38 
NO YES 
  36 
 
 1 
 2 
 3 
4. I understand that my participation in the interview is voluntary and that 4 
I am free to withdraw from the study at any time, without having to give 5 
a reason. 6 
 7 
5. I understand that the interview will be recorded on a digital recorder.  8 
I give permission for doing this.  9 
 10 
6. I understand that the recordings will be saved on a secure computer                             11 
at the University of East Anglia. The recordings will be destroyed                                    12 
at the end of the study. The transcripts will be kept for 15 years. 13 
 14 
7. I consent to the storage including electronic, of personal information for 15 
the purposes of this study. I understand that any information that could  16 
identify me will be kept strictly confidential and that no personal  17 
information will be included in the study report, my thesis, or other 18 
publication. 19 
 20 
8. I understand that what I say during the interview is confidential, in  21 
accordance with the Data Protection Act. However, you must be aware 22 
that if you tell the interviewer something which shows that there is a  23 
significant risk to you or someone else, they may need to pass this 24 
information on. 25 
If this happens, they will discuss it with you first before anyone else is 26 
told 27 
 28 
9. I am happy to be contacted to receive updates on how the study is              29 
progressing and to be informed about the results of the study  30 
           at the end. 31 
 32 
10. I give permission for a copy of this consent form to be kept confidentially 33 
and securely by the Norwich Clinical Trials Unit. 34 
 35 
11. I agree to take part in an interview for the above study. 36 
 37 
 38 
Qualitative Interviews CADOM study Version 1.2, 1st May 2018  39 
IRAS 222668 40 
 41 
 
 
 
NO YES 
  37 
 
 1 
 2 
……………………………………….                ……………...                ……………………………………. 3 
Name of the patient (Print)      Date         Patient’s signature  4 
 5 
……………………………………….                ……………...              ……………………………………….       6 
Name of person taking consent       Date                   Signature 7 
(Print) 8 
 9 
Original to be retained and filed in the site file. 1 copy to patient, 1 copy to be 10 
filed in patient’s notes 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
Qualitative Interviews CADOM study Version 1.2, 1st May 2018  25 
IRAS 222668 26 
 27 
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Supplementary File 1 – SPIRIT Checklist 1 
SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and 2 
related documents* 3 
Section/item I
t
e
m 
N
o 
Description Addresse
d on page 
number 
Administrative information 
 
Title 1 Descriptive title identifying the study design, population, 
interventions, and, if applicable, trial acronym 
1 
Trial 
registration 
2
a 
Trial identifier and registry name. If not yet registered, name 
of intended registry 
5 
2
b 
All items from the World Health Organization Trial 
Registration Data Set 
yes 
Protocol 
version 
3 Date and version identifier 16 
Funding 4 Sources and types of financial, material, and other support 23 
Roles and 
responsibilitie
s 
5
a 
Names, affiliations, and roles of protocol contributors 1-3 
5
b 
Name and contact information for the trial sponsor 23 
 5
c 
Role of study sponsor and funders, if any, in study design; 
collection, management, analysis, and interpretation of data; 
writing of the report; and the decision to submit the report for 
publication, including whether they will have ultimate authority 
over any of these activities 
23 
 5
d 
Composition, roles, and responsibilities of the coordinating 
centre, steering committee, endpoint adjudication committee, 
data management team, and other individuals or groups 
overseeing the trial, if applicable (see Item 21a for data 
monitoring committee) 
N/A 
Introduction 
   
  39 
 
Background 
and rationale 
6
a 
Description of research question and justification for 
undertaking the trial, including summary of relevant studies 
(published and unpublished) examining benefits and harms 
for each intervention 
6-10 
 6
b 
Explanation for choice of comparators 8-10 
Objectives 7 Specific objectives or hypotheses 10-11 
Trial design 8 Description of trial design including type of trial (eg, parallel 
group, crossover, factorial, single group), allocation ratio, and 
framework (eg, superiority, equivalence, noninferiority, 
exploratory) 
11 
Methods: Participants, interventions, and outcomes  
Study setting 9 Description of study settings (eg, community clinic, academic 
hospital) and list of countries where data will be collected. 
Reference to where list of study sites can be obtained 
12 
Eligibility 
criteria 
1
0 
Inclusion and exclusion criteria for participants. If applicable, 
eligibility criteria for study centres and individuals who will 
perform the interventions (eg, surgeons, psychotherapists) 
12-13,24 
Interventions 1
1
a 
Interventions for each group with sufficient detail to allow 
replication, including how and when they will be administered 
15 
1
1
b 
Criteria for discontinuing or modifying allocated interventions 
for a given trial participant (eg, drug dose change in response 
to harms, participant request, or improving/worsening 
disease) 
N/A 
1
1
c 
Strategies to improve adherence to intervention protocols, 
and any procedures for monitoring adherence (eg, drug tablet 
return, laboratory tests) 
16 
1
1
d 
Relevant concomitant care and interventions that are 
permitted or prohibited during the trial 
16,27 
  40 
 
Outcomes 1
2 
Primary, secondary, and other outcomes, including the 
specific measurement variable (eg, systolic blood pressure), 
analysis metric (eg, change from baseline, final value, time to 
event), method of aggregation (eg, median, proportion), and 
time point for each outcome. Explanation of the clinical 
relevance of chosen efficacy and harm outcomes is strongly 
recommended 
25 
Participant 
timeline 
1
3 
Time schedule of enrolment, interventions (including any run-
ins and washouts), assessments, and visits for participants. A 
schematic diagram is highly recommended (see Figure) 
27 
Sample size 1
4 
Estimated number of participants needed to achieve study 
objectives and how it was determined, including clinical and 
statistical assumptions supporting any sample size 
calculations 
12 
Recruitment 1
5 
Strategies for achieving adequate participant enrolment to 
reach target sample size 
12 
Methods: Assignment of interventions (for controlled trials) 
12 
Allocation:    
Sequence 
generation 
1
6
a 
Method of generating the allocation sequence (eg, computer-
generated random numbers), and list of any factors for 
stratification. To reduce predictability of a random sequence, 
details of any planned restriction (eg, blocking) should be 
provided in a separate document that is unavailable to those 
who enrol participants or assign interventions 
12 
Allocation 
concealme
nt 
mechanis
m 
1
6
b 
Mechanism of implementing the allocation sequence (eg, 
central telephone; sequentially numbered, opaque, sealed 
envelopes), describing any steps to conceal the sequence 
until interventions are assigned 
12 
Implement
ation 
1
6
c 
Who will generate the allocation sequence, who will enrol 
participants, and who will assign participants to interventions 
12 
Blinding 
(masking) 
1
7
a 
Who will be blinded after assignment to interventions (eg, trial 
participants, care providers, outcome assessors, data 
analysts), and how 
11 
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 1
7
b 
If blinded, circumstances under which unblinding is 
permissible, and procedure for revealing a participant’s 
allocated intervention during the trial 
N/A 
Methods: Data collection, management, and analysis 
 
Data 
collection 
methods 
1
8
a 
Plans for assessment and collection of outcome, baseline, 
and other trial data, including any related processes to 
promote data quality (eg, duplicate measurements, training of 
assessors) and a description of study instruments (eg, 
questionnaires, laboratory tests) along with their reliability and 
validity, if known. Reference to where data collection forms 
can be found, if not in the protocol 
25 
 1
8
b 
Plans to promote participant retention and complete follow-up, 
including list of any outcome data to be collected for 
participants who discontinue or deviate from intervention 
protocols 
16 
Data 
management 
1
9 
Plans for data entry, coding, security, and storage, including 
any related processes to promote data quality (eg, double 
data entry; range checks for data values). Reference to where 
details of data management procedures can be found, if not in 
the protocol 
18 
Statistical 
methods 
2
0
a 
Statistical methods for analysing primary and secondary 
outcomes. Reference to where other details of the statistical 
analysis plan can be found, if not in the protocol 
16-18 
 2
0
b 
Methods for any additional analyses (eg, subgroup and 
adjusted analyses) 
N/A 
 2
0
c 
Definition of analysis population relating to protocol non-
adherence (eg, as randomised analysis), and any statistical 
methods to handle missing data (eg, multiple imputation) 
N/A 
Methods: Monitoring 
 
Data 
monitoring 
2
1
a 
Composition of data monitoring committee (DMC); summary 
of its role and reporting structure; statement of whether it is 
independent from the sponsor and competing interests; and 
reference to where further details about its charter can be 
found, if not in the protocol. Alternatively, an explanation of 
why a DMC is not needed 
19 
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 2
1
b 
Description of any interim analyses and stopping guidelines, 
including who will have access to these interim results and 
make the final decision to terminate the trial 
N/A 
Harms 2
2 
Plans for collecting, assessing, reporting, and managing 
solicited and spontaneously reported adverse events and 
other unintended effects of trial interventions or trial conduct 
19 
Auditing 2
3 
Frequency and procedures for auditing trial conduct, if any, 
and whether the process will be independent from 
investigators and the sponsor 
18-19 
Ethics and dissemination  
Research 
ethics 
approval 
2
4 
Plans for seeking research ethics committee/institutional 
review board (REC/IRB) approval 
22 
Protocol 
amendments 
2
5 
Plans for communicating important protocol modifications (eg, 
changes to eligibility criteria, outcomes, analyses) to relevant 
parties (eg, investigators, REC/IRBs, trial participants, trial 
registries, journals, regulators) 
22 
Consent or 
assent 
2
6
a 
Who will obtain informed consent or assent from potential trial 
participants or authorised surrogates, and how (see Item 32) 
13 
 2
6
b 
Additional consent provisions for collection and use of 
participant data and biological specimens in ancillary studies, 
if applicable 
22 
Confidentialit
y 
2
7 
How personal information about potential and enrolled 
participants will be collected, shared, and maintained in order 
to protect confidentiality before, during, and after the trial 
18 
Declaration 
of interests 
2
8 
Financial and other competing interests for principal 
investigators for the overall trial and each study site 
23 
Access to 
data 
2
9 
Statement of who will have access to the final trial dataset, 
and disclosure of contractual agreements that limit such 
access for investigators 
22 
Ancillary and 
post-trial care 
3
0 
Provisions, if any, for ancillary and post-trial care, and for 
compensation to those who suffer harm from trial participation 
22 
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Disseminatio
n policy 
3
1
a 
Plans for investigators and sponsor to communicate trial 
results to participants, healthcare professionals, the public, 
and other relevant groups (eg, via publication, reporting in 
results databases, or other data sharing arrangements), 
including any publication restrictions 
20 
 3
1
b 
Authorship eligibility guidelines and any intended use of 
professional writers 
23 
 3
1
c 
Plans, if any, for granting public access to the full protocol, 
participant-level dataset, and statistical code 
N/A 
Appendices 
   
Informed 
consent 
materials 
3
2 
Model consent form and other related documentation given to 
participants and authorised surrogates 
32-37 
Biological 
specimens 
3
3 
Plans for collection, laboratory evaluation, and storage of 
biological specimens for genetic or molecular analysis in the 
current trial and for future use in ancillary studies, if applicable 
N/A 
 1 
